Kolexia
Allangba Olivier Hématologie
Allangba Olivier
Hématologie
Centre Hospitalier de Saint Brieuc
Saint-Brieuc, France
75 Activités
11 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Myélome multiple Tumeurs à plasmocytes Aberrations des chromosomes Anémie Exanthème Syndromes myéloprolifératifs Neutropénie Thrombopénie Translocation génétique

Collaborateurs

Voir plus
Launay Vincent
Launay Vincent
Centre Hospitalier de Saint Brieuc, Saint-Brieuc, France
Dagorne Anaig
Dagorne Anaig
Centre Hospitalier de Saint Brieuc, Saint-Brieuc, France
Martiniuc Iuliana
Martiniuc Iuliana
Centre Hospitalier de Saint Brieuc, Saint-Brieuc, France
Nivet Thomas
Nivet Thomas
Centre Hospitalier de Saint Brieuc, Saint-Brieuc, France

Industries

Voir plus
A+A
76 collaboration(s)
Dernière en 2023
IQVIA
40 collaboration(s)
Dernière en 2023
B3TSI
37 collaboration(s)
Dernière en 2023
Janssen
26 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study.
Haematologica   01 octobre 2023
PCD: A Multicenter Open Label Phase II Study of Pomalidomide and Cyclophosphamide and Dexamethasone in Relapse/Refractory Multiple Myeloma Patients Who Were First Treated Within the IFM/DFCI 2009 Trial
Essai Clinique (Celgene)   03 juillet 2023
Efficacy of anti-PD1 therapy in relapsed or refractory NK/T cell lymphoma: a matched cohort analysis from the LYSA
17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 ‐ 17 June, 2023   09 juin 2023
A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma: A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral Ixazomib (MLN9708) Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Essai Clinique (Takeda Pharmaceutical)   07 février 2023
Phase II Study of the Combination of Pomalidomide with Dexamethasone As Maintenance Therapy after First Relapse Treatment with PCD Followed or Not By Autologous Stem Cell Transplant in Multiple Myeloma Patients
Blood   23 novembre 2021
Long-term follow-up of JAK2 exon 12 polycythemia vera: a French Intergroup of Myeloproliferative Neoplasms (FIM) study.
Leukemia   21 juillet 2020
Sequential mutational evaluation of CALR -mutated myeloproliferative neoplasms with thrombocytosis reveals an association between CALR allele burden evolution and disease progression.
British journal of haematology   11 novembre 2019
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma.
Blood   03 octobre 2018
Switches of tyrosine-kinase inhibitors in chronic phase of chronic myeloid leukemia in real life.
American journal of hematology   30 septembre 2018
A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial.
Leukemia   26 avril 2018